Caribou Biosciences Stock

cariboubio.comHealthcare / BioTech & PharmaFounded: 2011Funding to Date: $41.55MM

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Caribou Biosciences before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Caribou Biosciences before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Caribou Biosciences’ Stock

Can you buy Caribou Biosciences’ stock?
You can no longer buy Caribou Biosciences’ stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell Caribou Biosciences’ stock?
You can no longer sell stock of Caribou Biosciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
What is Caribou Biosciences’ stock price?
The stock price of Caribou Biosciences is $5.38 as of 1/18/24.
What is Caribou Biosciences’ stock ticker symbol?
The ticker symbol of Caribou Biosciences is CRBU.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.


Management Team

Barbara McClung
Chief Legal Officer and Corporate Secretary
Timothy Herpin Ph.D
Chief Business Officer
Chris Fuller
Vice President, Informatics
Jennifer Doudna Ph.D
Co-Founder & Scientific Advisor
Steven Kanner Ph.D
Chief Scientific Officer
Edny Inui
Director, Business Development
James Berger
Rachel Haurwitz Ph.D
Co-Founder, Board Member, President and Chief Executive Officer
Martin Jinek Ph.D
Co-Founder & Scientific Advisor
Scott Gradia Ph.D
Vice President of Platform Research

Board Members

Philip Austin
Anterra Capital
Robert Weisskoff Ph.D
Natalie Sacks MD
Rachel Haurwitz Ph.D


Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering wi
Updated on: Jun 13, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.